CN113855750A - Traditional Chinese medicine prescription and preparation for preventing and treating mild cognitive impairment - Google Patents

Traditional Chinese medicine prescription and preparation for preventing and treating mild cognitive impairment Download PDF

Info

Publication number
CN113855750A
CN113855750A CN202111172422.3A CN202111172422A CN113855750A CN 113855750 A CN113855750 A CN 113855750A CN 202111172422 A CN202111172422 A CN 202111172422A CN 113855750 A CN113855750 A CN 113855750A
Authority
CN
China
Prior art keywords
chinese medicine
cognitive impairment
traditional chinese
mild cognitive
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111172422.3A
Other languages
Chinese (zh)
Inventor
苏同生
万兆新
陈艳懂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202111172422.3A priority Critical patent/CN113855750A/en
Publication of CN113855750A publication Critical patent/CN113855750A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/69—Polygalaceae (Milkwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718—Coptis (goldthread)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a traditional Chinese medicine prescription for preventing and treating mild cognitive impairment and a preparation, the prescription comprises: 10-14g of polygala root, 7-11g of ginseng, 10-14g of coptis root, 16-20g of rhizoma acori graminei, 13-17g of white poria and 0.3-0.7g of curcumin; the method comprises the following steps: mixing the above four raw materials at a certain weight ratio, placing into a container, mixing, adding 10 times of water, and soaking for 30 min; step two: decocting for 3 times, wherein the extractive solution is coarsely filtered for 3 times during the decocting process, and concentrated to 1.2 g.mL-1 mass concentration at-80 deg.C to obtain mixed extractive solution, and placing into a refrigerator at 4 deg.C for use; step three: extracting Curcuma rhizome with ethanol concentration of 72% at a solid-to-liquid ratio of 1:16 for 91min to obtain Curcuma rhizome extractive solution or directly adding curcumin; the traditional Chinese medicine prescription and the preparation for preventing and treating mild cognitive impairment provided by the invention can effectively treat mild cognitive impairment, and the traditional Chinese medicine prescription is simple in preparation process, healthy and free of adverse side effects.

Description

Traditional Chinese medicine prescription and preparation for preventing and treating mild cognitive impairment
Technical Field
The invention belongs to the technical field of prevention and treatment of mild cognitive impairment, and particularly relates to a traditional Chinese medicine prescription and a preparation for prevention and treatment of mild cognitive impairment.
Background
Mild cognitive impairment is a transitional state between normal aging and dementia, and is clinically manifested by cognitive impairment and memory decline. According to statistics, the total number of MCI patients exceeds 2400 ten thousand, wherein at least 10-15% of MCI patients can be converted into Alzheimer disease every year, but at present, the AD has no specific drugs, so that the effective inhibition or delay of the MCI disease course has important significance for preventing the AD from happening.
MCI and AD belong to the categories of amnesia and amnesia in traditional Chinese medicine, the main pathogenesis of MCI and AD is kidney essence deficiency and phlegm covering the spirit, and the treatment focuses on tonifying kidney to resolve phlegm and inducing resuscitation to refresh the mind. The research shows that the kidney tonifying, phlegm reducing, resuscitation inducing and resuscitation inducing prescription such as Kaixiong powder, Polygala tenuifolia powder and Hui decoction can improve the symptoms of the MCI and the AD by inhibiting the generation of A beta, relieving the toxicity of the A beta, reducing the phosphorylation of Tau protein, inhibiting neuroinflammation, promoting neurogenesis and the like, and the discovery shows that ginseng and rhizoma acori graminei are the core medicine pair for improving the MCI and the AD. Under the single-level and single-system research technology, previous researches still fail to completely disclose the action mechanisms of the kidney-tonifying, phlegm-reducing, resuscitation-inducing and resuscitation-inducing formulas such as the Kaixan powder, the Polygala root powder and the Hui decoction, which are multi-level and multi-system and can integrally regulate MCI and AD.
Therefore, the traditional Chinese medicine prescription for preventing and treating the mild cognitive impairment is of great significance for treating the mild cognitive impairment.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine prescription and a preparation for preventing and treating mild cognitive impairment, and aims to solve the problems in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme: a traditional Chinese medicine prescription for preventing and treating mild cognitive impairment comprises the following components: 10-14g of polygala root, 7-11g of ginseng, 10-14g of coptis root, 16-20g of rhizoma acori graminei, 13-17g of white poria and 0.3-0.7g of curcumin.
The traditional Chinese medicine preparation for preventing and treating mild cognitive impairment comprises the formula, and is characterized in that: the method comprises the following steps: mixing the above four raw materials at a certain weight ratio, placing into a container, mixing, adding 10 times of water, and soaking for 30 min;
step two: decocting for 3 times, wherein the extractive solution is coarsely filtered for 3 times during the decocting process, and concentrated to 1.2 g.mL-1 mass concentration at-80 deg.C to obtain mixed extractive solution, and placing into a refrigerator at 4 deg.C for use;
step three: extracting Curcuma rhizome with ethanol concentration of 72% at a solid-to-liquid ratio of 1:16 for 91min to obtain Curcuma rhizome extractive solution or directly adding curcumin;
step four: spray drying the obtained mixed extract with curcumin extractive solution; the spray dried powder was processed into cube cubes weighing about 5 grams.
Preferably, in the fourth step, a cutting pulverizer is used for pulverizing the spray-dried powder into particles which are sieved by a 10-mesh sieve, wherein the mass fraction of the fine powder sieved by the 80-mesh sieve is less than 20%.
Preferably, the mixed extract obtained in the second step is stored in a refrigerator at 4 ℃ in a sealing way.
Preferably, the administration method comprises: 15g/3 times/day or placing the Chinese medicinal materials in casserole or casserole, adding 400ml of water, soaking in cold water for 20min, boiling with strong fire, decocting with slow fire for 10min, and taking the decoction for warm administration three times in the morning, at noon and evening.
Compared with the prior art, the invention has the beneficial effects that: the traditional Chinese medicine prescription and the preparation for preventing and treating mild cognitive impairment provided by the invention can effectively treat mild cognitive impairment, and the traditional Chinese medicine prescription is simple in preparation process, healthy and free of adverse side effects.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The invention provides a technical scheme that: a traditional Chinese medicine prescription for preventing and treating mild cognitive impairment comprises the following components: 12g of polygala root, 9g of ginseng, 12g of coptis root, 18g of rhizoma acori graminei, 15g of white poria and 0.5g of curcumin.
A traditional Chinese medicine preparation for preventing and treating mild cognitive impairment comprises the following components in part by weight: mixing the above four raw materials at a certain weight ratio, placing into a container, mixing, adding 10 times of water, and soaking for 30 min;
step two: decocting for 3 times, wherein the extractive solution is coarsely filtered for 3 times during the decocting process, and concentrated to 1.2 g.mL-1 mass concentration at-80 deg.C to obtain mixed extractive solution, and placing into a refrigerator at 4 deg.C for use;
step three: extracting Curcuma rhizome with ethanol concentration of 72% at a solid-to-liquid ratio of 1:16 for 91min to obtain Curcuma rhizome extractive solution or directly adding curcumin;
step four: spray drying the obtained mixed extract with curcumin extractive solution; the spray dried powder was processed into cube cubes weighing about 5 grams.
In this embodiment, preferably, in the fourth step, the spray-dried powder is pulverized to particles by using a cutting pulverizer, and the particles are sieved by a 10-mesh sieve, wherein the mass fraction of fine powder sieved by an 80-mesh sieve is less than 20%.
In this embodiment, preferably, the mixed extract obtained in step two needs to be stored in a sealed manner when being placed in a refrigerator at 4 ℃ for standby.
In this embodiment, the administration method is preferably: 15g/3 times/day or placing the Chinese medicinal materials in casserole or casserole (not decocting with cuprum), adding 400ml water, soaking in cold water for 20min, boiling with strong fire, decocting with slow fire for 10min, and taking the decoction for warm administration three times in the morning, at noon and evening. The treatment period is 3 months.
To investigate the effectiveness of the present recipe, we developed ethical-based clinical observations, which were tested as follows:
1. conventional treatment regimens:
i.e., the basic conventional treatment regimen employed in the treatment, which comprises:
(1) basic treatment of western medicines: controlling blood pressure by medication; ② platelet aggregation resistance; regulating fat and stabilizing spots; fourthly, controlling blood sugar; and reducing blood homocysteine.
(2) Non-drug treatment: comprehensive training of hemiplegic limbs and cognitive rehabilitation training.
2. Grouping treatment:
2.1 control group
(1) Control group i: the polygala root powder is added to the conventional treatment scheme for treatment.
The treatment method comprises the following steps: the polygala root powder is prepared from 12g of honey polygala root, 9g of ginseng, 12g of coptis root, 18g of rhizoma acori graminei and 15g of white poria.
Control group ii: curry cubes were added to the conventional treatment regimen.
The treatment method comprises the following steps: the product is prepared into dices with curcumin, and is taken 2-3 times per week, and each dice contains 0.5g curry.
2.2 treatment groups
The formulations of the present invention are administered to patients concurrently with oral administration on a conventional treatment regimen. The treatment period is 3 months.
3. Observation index
3.1 general case
Gender, age, course of disease, age of education, MMSE, BDI.
3.2 behavioral indicators
(1) And (3) evaluating the memory: the Huashan version auditory words test (AVLT-H);
(2) and (4) performing function evaluation: wire test (STT A-B);
(3) language fluency assessment: animal word fluency (AFT), boston designation test (BNT);
(4) assessment of overall cognitive function: simple mental state examination scale (MMSE);
(5) evaluating the daily life capacity: social function questionnaires (FAQs).
4. Evaluation of safety
Adverse events refer to any unexpected symptoms, signs, or health condition that occurred after initiation of treatment in this study, and do not necessarily have a causal relationship to treatment in this study; all adverse events were recorded and the information on adverse events was as follows:
table 1 adverse event information registration
Figure BDA0003293803600000051
TABLE 2 evaluation criteria for safety
Figure BDA0003293803600000061
5. Statistical analysis
Analyzing the test data by SPSS21.0 software, testing the measured data, and adopting mean plus or minus standard deviation if the distribution is normal or uniform
Figure BDA0003293803600000062
The three groups are compared by adopting one-factor analysis of variance, and the self front and back comparison in the groups adopts matched sample T test; adopting a nonparametric test method (Kruskal-Wallis H rank sum test) when the abnormal distribution or variance is irregular; checking the counting data by a chi-square method; when P < 0.05, the difference is statistically significant.
Test results and analysis
Applying the upper part to screen 64 patients in total strictly according to inclusion and exclusion standards, and randomly dividing the patients into three groups according to the group-entering sequence; 1 case in the control group I is rejected due to mistaking, and 1 case is generally treated and automatically quits the test; finally 61 patients were involved in the completion of the trial; 20 cases of a control group I (treated by polygala tenuifolia powder on a conventional scheme), 19 cases of a control group II (treated by curry on a conventional scheme) and 22 cases of a treatment group (treated by the formula of the invention on a conventional scheme).
1.1 general data analysis
Through statistical analysis, the three groups of patients have no significant difference in sex, age, disease course, education period, MMSE and BDI comparison (P is more than 0.05) and are comparable (tables 1-6).
TABLE 13 comparison of gender composition of the Subjects
Figure BDA0003293803600000063
Figure BDA0003293803600000071
Note: by Chi-square test, x2＝0.811，P＝0.667＞0.05。
TABLE 23 age-average comparison of the groups of subjects
Figure BDA0003293803600000072
Figure BDA0003293803600000073
Note: through one-way anova, F is 0.880, and P is 0.420 > 0.05.
TABLE 33 mean disease progression comparisons for the groups of subjects
Figure BDA0003293803600000074
Figure BDA0003293803600000075
Note: through one-way analysis of variance, F is 0.652, and P is 0.525 > 0.05.
TABLE 43 cultural mean comparison of the Subjects
Figure BDA0003293803600000076
Figure BDA0003293803600000077
Note: by one-way anova, F is 1.428 and P is 0.248 > 0.05.
Table 53 MMSE mean comparisons for groups of subjects
Figure BDA0003293803600000078
Figure BDA0003293803600000079
Note: by one-way anova, F is 0.769, and P is 0.468 & gt 0.05.
TABLE 63 mean BDI comparisons for groups of subjects
Figure BDA00032938036000000710
Figure BDA0003293803600000081
Note: through the rank-sum test, H is 3.644, and P is 0.162 > 0.05.
1.2 clinical observations
1.2.1 comparison before and after treatment of memory function in three groups of patients
Comparison in group: the three treatment protocols can improve AVLT-H total score and sensitivity index (P is less than 0.05), especially immediate recall and recognizability of the control group I and the treatment group (P is less than 0.01); comparison between groups: after 3 months, the AVLT-H total scores of three groups of patients are compared (P is less than 0.01) through single-factor variance analysis; the AVLT-H total score and sensitivity index of the patients in the treatment group are obviously superior to those of the two control groups, the AVLT-H total score and long-delay recall are not obviously different between the two control groups (P is more than 0.05), but the immediate recall and recognizability of the patients in the control group I are superior to those in the group II (tables 7 to 8).
Table 73 group of patients had a pre-and post-treatment AVLT-H comparison (score,
Figure BDA0003293803600000082
)
Figure BDA0003293803600000083
note: AVLT-H: the Chinese version auditory word learning test; the group comparison adopts a matched sample t test, and a represents the self front-back comparison; the comparison among groups is carried out by single-factor anova, and b represents the comparison between the control groups I and II and the treatment group; marked by P < 0.05 and # P < 0.01, and has statistical significance.
Table 83 group of patients had a pre-and post-treatment AVLT-H comparison (score,
Figure BDA0003293803600000084
)
Figure BDA0003293803600000091
note: AVLT-H: the Chinese version auditory word learning test; the group comparison adopts a matched sample t test, and a represents the self front-back comparison; comparing between groups by single factor analysis of variance, b comparing control group I and II with treatment group, c comparing control group I with control group II; marked by P < 0.05 and # P < 0.01, and has statistical significance.
1.2.2 three groups of patients performed before and after comparison with language function treatment
Three groups of patients were analyzed for STT-A, STT-B, AFT and BNT data, and compared in groups: the three groups of the proposal have improvement effects (P < 0.05) in the executive function and the language function, wherein the improvement of the treatment group and the group I in the executive function is stronger than that of the group II (P < 0.01), and the improvement of the treatment group in the language function is more obvious than that of the control group I and the group II (P < 0.01); comparison between groups: after 3 months, the STT-A, STT-B scores of the patients in the treatment group were better than those in the control groups I and II (P < 0.05), while the scores of AFT and BNT in the control groups were not significantly different (P > 0.05) (Table 9-Table 10).
Table 93 group subjects pre and post treatment STT-A, STT-B comparison (score,
Figure BDA0003293803600000092
)
Figure BDA0003293803600000093
Figure BDA0003293803600000101
note: STT-A, STT-B: performing function evaluation; the group comparison adopts a matched sample t test, and a represents the self front-back comparison; the comparison among groups is carried out by single-factor anova, and b represents the comparison between the control groups I and II and the treatment group; marked by P < 0.05 and # P < 0.01, and has statistical significance.
Table 103 setComparison of AFT and BNT before and after treatment of subjects (score,
Figure BDA0003293803600000102
)
Figure BDA0003293803600000103
note: AFT: testing fluency of animal words, BNT is a Boston naming test; the group comparison adopts a matched sample t test, and a represents the self front-back comparison; the comparison among groups is analyzed by single factor variance, P is more than 0.05, the difference is not obvious, and the statistical significance is avoided; marked by P < 0.05 and # P < 0.01, and has statistical significance.
1.2.3 comparison of overall cognitive function and ability to daily Life of three groups of patients before and after treatment
Comparison in group: the three groups of treatment regimens are all effective in improving overall cognitive function and daily living capacity (P < 0.05), with the treatment group being predominant in improving overall cognitive function (P < 0.01); comparison between groups: after 3 months, the MMSE and FAQ scores of the patients in the treatment group are better than those in the control groups I and II (P is less than 0.05), wherein the MMSE score of the treatment group is far changed than that of the control group II (P is less than 0.01), and the MMSE and FAQ scores of the control groups I and II are not obviously different (P is more than 0.05) (see table 11).
Figure BDA0003293803600000111
Note: the group comparison adopts a matched sample t test, and a represents the self front-back comparison; the comparison among groups is carried out by single-factor anova, and b represents the comparison between the control groups I and II and the treatment group; marked by P < 0.05 and # P < 0.01, and has statistical significance.
2 analysis of study results
(1) Influence on memory function
The three groups of treatment schemes can improve the memory function, particularly the immediate memory and vocabulary recognizability, but the treatment groups can obviously improve the sensitive indexes (P is less than 0.01) such as the immediate memory, the long-delay memory and the recognizability;
(2) influencing execution and language functions
The three groups of the proposal have positive effects on executive function and language function, particularly STT-A, STT-B of patients in the control group I and the treatment group has better score change before and after than that in the group II (P is less than 0.01), and the treatment group has better executive function than that in the two control groups (P is less than 0.05); however, there was no significant difference (P > 0.05) between the three groups in terms of language function (AFT and BNT scores), only there was a trend in the difference, probably related to the smaller sample size.
(3) Influence on overall cognition and daily life ability
The overall cognitive ability and daily life ability of patients in a treatment group are more prominent, compared with the mean values of MMSE and FAQ scores in three groups, the treatment groups are 28.18 +/-1.89 and 0.64 +/-1.18 respectively, the control group I is 26.75 +/-2.6 and 1.80 +/-1.64 respectively, the control group II is 26.26 +/-2.58 and 1.26 +/-1.70 respectively, the MMSE and FAQ scores of patients in the treatment group are higher than those of the control groups I and II (P is less than 0.05), and particularly, the MMSE score is obviously higher than that of the group II (P is less than 0.01).
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.

Claims (5)

1. A traditional Chinese medicine prescription for preventing and treating mild cognitive impairment is characterized in that: the formula comprises the following components: 10-14g of polygala root, 7-11g of ginseng, 10-14g of coptis root, 16-20g of rhizoma acori graminei, 13-17g of white poria and 0.3-0.7g of curcumin.
2. A traditional Chinese medicine preparation for preventing and treating mild cognitive impairment, which comprises the formula composition in claim 1, and is characterized in that: the method comprises the following steps: mixing the above four raw materials at a certain weight ratio, placing into a container, mixing, adding 10 times of water, and soaking for 30 min;
step two: decocting for 3 times, wherein the extractive solution is coarsely filtered for 3 times during the decocting process, and concentrated to 1.2 g.mL-1 mass concentration at-80 deg.C to obtain mixed extractive solution, and placing into a refrigerator at 4 deg.C for use;
step three: extracting Curcuma rhizome with ethanol concentration of 72% at a solid-to-liquid ratio of 1:16 for 91min to obtain Curcuma rhizome extractive solution or directly adding curcumin;
step four: spray drying the obtained mixed extract with curcumin extractive solution; the spray dried powder was processed into cube cubes weighing about 5 grams.
3. The traditional Chinese medicine preparation for preventing and treating mild cognitive impairment according to claim 2, which is characterized in that: and in the fourth step, a cutting pulverizer is used for pulverizing the spray-dried powder into particles which are sieved by a 10-mesh sieve, wherein the mass fraction of the fine powder sieved by the 80-mesh sieve is less than 20%.
4. The traditional Chinese medicine prescription and preparation for preventing and treating mild cognitive impairment according to claim 2, wherein: and (5) when the mixed extracting solution obtained in the step two is placed into a refrigerator with the temperature of 4 ℃ for standby, sealing and storing the mixed extracting solution.
5. The traditional Chinese medicine prescription and preparation for preventing and treating mild cognitive impairment according to claim 2, wherein: the taking method comprises the following steps: 15g/3 times/day or placing the Chinese medicinal materials in casserole or casserole, adding 400ml of water, soaking in cold water for 20min, boiling with strong fire, decocting with slow fire for 10min, and taking the decoction for warm administration three times in the morning, at noon and evening.
CN202111172422.3A 2021-10-08 2021-10-08 Traditional Chinese medicine prescription and preparation for preventing and treating mild cognitive impairment Pending CN113855750A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111172422.3A CN113855750A (en) 2021-10-08 2021-10-08 Traditional Chinese medicine prescription and preparation for preventing and treating mild cognitive impairment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111172422.3A CN113855750A (en) 2021-10-08 2021-10-08 Traditional Chinese medicine prescription and preparation for preventing and treating mild cognitive impairment

Publications (1)

Publication Number Publication Date
CN113855750A true CN113855750A (en) 2021-12-31

Family

ID=79002022

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111172422.3A Pending CN113855750A (en) 2021-10-08 2021-10-08 Traditional Chinese medicine prescription and preparation for preventing and treating mild cognitive impairment

Country Status (1)

Country Link
CN (1) CN113855750A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101069734A (en) * 2006-05-10 2007-11-14 河北天时医药技术开发有限公司 Chinese medicine composition for vascular cretinism and preparing method therefor
CN101168025A (en) * 2007-10-25 2008-04-30 张占军 Medicine composition for preventing and treating senile dementia
CN110404011A (en) * 2019-08-19 2019-11-05 山西中医药大学 A kind of biocompatibility Radix Polygalae dissipates micro emulsion and the preparation method and application thereof
CN111840429A (en) * 2019-04-26 2020-10-30 武汉军谷坊科技开发有限公司 Traditional Chinese medicine formula and preparation for treating amnesia and insomnia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101069734A (en) * 2006-05-10 2007-11-14 河北天时医药技术开发有限公司 Chinese medicine composition for vascular cretinism and preparing method therefor
CN101168025A (en) * 2007-10-25 2008-04-30 张占军 Medicine composition for preventing and treating senile dementia
CN111840429A (en) * 2019-04-26 2020-10-30 武汉军谷坊科技开发有限公司 Traditional Chinese medicine formula and preparation for treating amnesia and insomnia
CN110404011A (en) * 2019-08-19 2019-11-05 山西中医药大学 A kind of biocompatibility Radix Polygalae dissipates micro emulsion and the preparation method and application thereof

Similar Documents

Publication Publication Date Title
Bahrke et al. Evaluation of the ergogenic properties of ginseng: an update
Panossian Adaptogens in mental and behavioral disorders
Lekomtseva et al. Rhodiola rosea in subjects with prolonged or chronic fatigue symptoms: results of an open-label clinical trial
Bahrke et al. Is ginseng an ergogenic aid?
Kwon et al. Efficacy and safety of auricular acupuncture for cognitive impairment and dementia: a systematic review
Gerontakos et al. Focus: Plant-based Medicine and Pharmacology: A Critical Review to Identify the Domains Used to Measure the Effect and Outcome of Adaptogenic Herbal Medicines
Klimova et al. Alzheimer's disease and Chinese medicine as a useful alternative intervention tool: a mini-review
CN103230602A (en) Method for evaluating effectiveness and safety of anti-depression traditional Chinese medicine composition in treating mild/moderate depression
US11278584B2 (en) Pharmaceutical composition for preventing and treating senile dementia and preparation method thereof
Kan et al. A botanical product containing Cistanche and Ginkgo extracts potentially improves chronic fatigue syndrome symptoms in adults: a randomized, double-blind, and placebo-controlled study
Ulbricht et al. An evidence-based systematic review of belladonna by the natural standard research collaboration
Hovhannisyan et al. Efficacy of Adaptogenic Supplements on Adapting to Stress: A Randomized, Controlled Trial. J Athl Enhancement 4: 4
CN113855750A (en) Traditional Chinese medicine prescription and preparation for preventing and treating mild cognitive impairment
CN102600372B (en) Chinese medicinal composition for preventing Parkinsonism
CN108904596B (en) Composition with memory improving effect
CN111939237B (en) Composition for improving memory and preparation method thereof
Nawaz et al. Evaluation of acute and repeated dose toxicity of the polyherbal formulation linkus syrup in experimental animals
RU2320359C2 (en) Decoction &#34;yian&#34; for ceasing narcotic dependence
CN108143929B (en) Medicine for treating vascular dementia
CN109200158B (en) Combined medicine for treating Alzheimer disease
CN112206283A (en) Traditional Chinese medicine composition for relieving physical fatigue and preparation method thereof
CN112274581A (en) Traditional Chinese medicine composition for treating cerebral apoplexy cognitive disorder diseases and application thereof
CN107029164B (en) Pure traditional Chinese medicine composition for treating cognitive function reduction and pure traditional Chinese medicine preparation prepared from same
CN109999155B (en) Traditional Chinese medicine composition for treating Alzheimer disease and preparation method thereof
US20180333449A1 (en) Herbo-mineral formulation for the treatment of cardio vascular diseases and method of preparation thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination